CureVac Acquisition Finalized as BioNTech Secures Controlling Stake
Published on 12/12/2025 at 10:16 | Redaktion boerse-global.de
The fate of CureVac’s independent stock market journey has been sealed. BioNTech has successfully cleared the final hurdle for its takeover, having received tenders for a decisive majority of CureVac’s outstanding shares. This move effectively concludes CureVac’s standalone trading narrative, transitioning to a technical settlement process with significant implications for remaining shareholders.
BioNTech has formally announced that the central condition of its offer has been met. By the close of the initial acceptance period, approximately 81.74% of all CureVac shares had been tendered. This outcome makes the acquisition a fait accompli, setting in motion an irreversible integration into the BioNTech corporate structure.
Consequently, the CureVac share Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
